Pharmaceutical The European Commission (EC) has approved Orencia (abatacept) alone or in combination with methotrexate for the treatment of active psoriatic arthritis (PsA) adult patients for whom the response to previous disease-modifying antirheumatic drug (DMARD) therapy, including methotrexate, has been inadequate, and additional systemic therapy for psoriatic skin lesions is not required. 27 July 2017